%0 Journal Article
%T Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
%A van Heek L
%A Weindler J
%A Gorniak C
%A Kaul H
%A Müller H
%A Mettler J
%A Baues C
%A Fuchs M
%A Borchmann P
%A Ferdinandus J
%A Dietlein M
%A Voltin CA
%A Kobe C
%A Roth KS
%J Eur J Haematol
%V 111
%N 6
%D 2023 Dec 29
%M 37644732
%F 3.674
%R 10.1111/ejh.14093
%X <B>OBJECTIVE: </B>The prognostic relevance of metabolic tumor volume (MTV) having recently been demonstrated in patients with early-stage favorable and advanced-stage Hodgkin lymphoma. The current study aimed to assess the potential prognostic value of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in early-stage unfavorable Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD17 trial.<BR><B>METHODS: </B>18 F-FDG PET/CT images were available for MTV analysis in 154 cases. We used three different threshold methods (SUV2.5 , SUV4.0 , and SUV41% ) to calculate MTV. Receiver-operating-characteristic analysis was performed to describe the value of these parameters in predicting an adequate therapy response. Therapy response was evaluated as PET negativity after 2 cycles of eBEACOPP followed by 2 cycles of ABVD.<BR><B>RESULTS: </B>All three threshold methods analyzed for MTV showed a positive correlation with the PET response after chemotherapy. Areas under the curve (AUC) were 0.70 (95% CI 0.53-0.87) and 0.65 (0.50-0.80) using the fixed thresholds of SUV4.0 and SUV2.5 , respectively, for MTV- calculation. The calculation of MTV using a relative threshold of SUV41% showed an AUC of 0.63 (0.47-0.79).<BR><B>CONCLUSIONS: </B>MTV does have predictive value after chemotherapy in early-stage unfavorable Hodgkin lymphoma, particularly when the fixed threshold of SUV4.0 is used for MTV calculation.<BR><B>BACKGROUND: </B>ClinicalTrials.gov NCT01356680.